EXEL vs. UTHR: Exelixis vs. United Therapeutics Stock Comparison
How do Exelixis (EXEL) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Exelixis (EXEL) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | EXEL | UTHR |
|---|---|---|
| Name | Exelixis Inc. | United Therapeutics Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.98 billion USD | 23.94 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | April 17, 2000 | June 17, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | EXEL | UTHR |
|---|---|---|
| Total Return (1Y) | 74.98% | 28.77% |
| Total Return (3Y, Annualized) | 50.33% | 37.63% |
| Total Return (5Y, Annualized) | 31.10% | 23.78% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | EXEL | UTHR |
|---|---|---|
| Volatility (1Y, Annualized) | 34.17% | 35.00% |
| Beta (5Y) | 0.41 | 0.49 |
| Max Drawdown (5Y) | -35.41% | -33.00% |
| Avg. Volume (3M) | 2.33M | 694.55K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | EXEL | UTHR |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 0.70 |
| Sortino Ratio (1Y) | 3.23 | 1.29 |
Profitability
ROE (TTM)
Both Exelixis (EXEL) at 44.32% and United Therapeutics (UTHR) at 19.13% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
44.32%
- Max
- 109.18%
- EXEL
- 44.32%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.13%
- Max
- 109.18%
- UTHR
- 19.13%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Exelixis (EXEL) at 35.45% and United Therapeutics (UTHR) at 38.61% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.45%
- EXEL
- 35.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.61%
- UTHR
- 38.61%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Exelixis (EXEL) at 40.75% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.75%
- Max
- 83.12%
- EXEL
- 40.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.99%
- Max
- 83.12%
- UTHR
- 28.99%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | EXEL | UTHR |
|---|---|---|
| ROE (TTM) | 44.32% | 19.13% |
| ROA (TTM) | 23.52% | 10.91% |
| Net Margin (TTM) | 35.45% | 38.61% |
| Operating Margin (TTM) | 40.75% | 28.99% |
| Gross Margin (TTM) | 96.26% | 86.34% |
Growth
Revenue Growth
Both Exelixis (EXEL) at 6.98% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Exelixis (EXEL) at 57.95% and United Therapeutics (UTHR) at 13.07% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | EXEL | UTHR |
|---|---|---|
| Revenue Growth (YoY) | 6.98% | 10.61% |
| Revenue Growth (3Y CAGR) | 12.93% | 18.02% |
| EPS Growth (YoY) | 57.95% | 13.07% |
| EPS Growth (3Y CAGR) | 70.59% | 22.92% |
Financial Strength
Current Ratio (MRQ)
Both Exelixis (EXEL) at 3.21 and United Therapeutics (UTHR) at 4.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.21
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- EXEL
- 3.21
- Q1
- 2.47
- Min
- 0.10
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- UTHR
- 4.61
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Exelixis (EXEL) carries debt-to-equity ratio of 0.09 against its industry range, while United Therapeutics (UTHR) reports no figure this period.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- EXEL
- 0.09
- Q1
- 0.02
- Min
- 0.00
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- UTHR
- --
Financial Strength Metrics
| Metric | EXEL | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 3.21 | 4.61 |
| Debt / Equity (MRQ) | 0.09 | -- |
| Net Debt / EBITDA | -0.71 | -1.53 |
Dividends
Dividend Yield (TTM)
Neither Exelixis (EXEL) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Exelixis (EXEL) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- UTHR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | EXEL | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Exelixis (EXEL) at 20.83 and United Therapeutics (UTHR) at 21.22 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.83
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- EXEL
- 20.83
- Q1
- 13.30
- Min
- 0.07
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.22
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- UTHR
- 21.22
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Exelixis (EXEL) at 6.80 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.80
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- EXEL
- 6.80
- Q1
- 3.01
- Min
- 0.01
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.51
- Max
- 58.18
- Q3
- 25.77
- UTHR
- 7.51
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
United Therapeutics (UTHR) at 3.80 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.28
- Max
- 13.53
- EXEL
- 9.28
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
UTHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.80
- Max
- 13.53
- Q3
- 6.54
- UTHR
- 3.80
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | EXEL | UTHR |
|---|---|---|
| P/E Ratio (TTM) | 20.83 | 21.22 |
| P/S Ratio (TTM) | 6.80 | 7.51 |
| P/B Ratio (MRQ) | 9.28 | 3.80 |
| Free Cash Flow Yield (TTM) | 4.47% | 1.90% |